NO912825D0 - Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper. - Google Patents

Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.

Info

Publication number
NO912825D0
NO912825D0 NO912825A NO912825A NO912825D0 NO 912825 D0 NO912825 D0 NO 912825D0 NO 912825 A NO912825 A NO 912825A NO 912825 A NO912825 A NO 912825A NO 912825 D0 NO912825 D0 NO 912825D0
Authority
NO
Norway
Prior art keywords
procedure
preparation
anionic groups
related peptides
immunogenic protein
Prior art date
Application number
NO912825A
Other languages
English (en)
Other versions
NO912825L (no
Inventor
William J Leanza
Stephen Marburg
Emilio A Emini
Richard L Tolman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO912825D0 publication Critical patent/NO912825D0/no
Publication of NO912825L publication Critical patent/NO912825L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
NO91912825A 1990-07-19 1991-07-18 Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper. NO912825L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55533990A 1990-07-19 1990-07-19
US55596690A 1990-07-19 1990-07-19
US71527891A 1991-06-19 1991-06-19
US71527691A 1991-06-19 1991-06-19

Publications (2)

Publication Number Publication Date
NO912825D0 true NO912825D0 (no) 1991-07-18
NO912825L NO912825L (no) 1992-01-20

Family

ID=27504782

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912825A NO912825L (no) 1990-07-19 1991-07-18 Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.

Country Status (11)

Country Link
US (1) US5606030A (no)
EP (1) EP0467700A3 (no)
JP (1) JPH07113038B2 (no)
KR (1) KR920002633A (no)
AU (1) AU8113591A (no)
CA (1) CA2047073A1 (no)
FI (1) FI913476A (no)
IE (1) IE912558A1 (no)
IL (1) IL98845A0 (no)
NO (1) NO912825L (no)
PT (1) PT98380A (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047033A1 (en) * 1990-07-19 1992-01-20 Elizabeth E. Sugg Cyclic hiv principal neutralizing determinant peptides
CA2047042A1 (en) * 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
CA2047078A1 (en) * 1990-07-19 1992-01-20 Steven S. Bondy Cyclic hiv principal neutralizing determinant peptides
CA2058876A1 (en) * 1991-12-19 1993-06-20 Maria A. Bednarek Cyclic hiv principal neutralizing determinant peptides
GB2271995A (en) * 1992-10-15 1994-05-04 Merck & Co Inc HIV peptide conjugated via anionic spacer to protein
GB2282380A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugate of epitopes of HIV with a protein complex from Neisseria
GB2282378A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugates of epitopes of HIV with a protein complex from Neisseria
US6664367B1 (en) * 1994-07-21 2003-12-16 Biosynthema, Inc. Stable analogs of bioactive peptides containing disulfide linkages
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
EP1098666B1 (en) * 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
DE19936715A1 (de) * 1999-08-06 2001-02-15 Ticona Gmbh Emissionsarme eingefärbte Polyoxymethylen-Formmassen
EP1290230A4 (en) * 2000-06-02 2004-10-20 Merck & Co Inc HEPATITIS C VIRUS CONJUGATE
ATE282205T1 (de) 2000-07-24 2004-11-15 Health Research Inc Verfahren zur detektion von prostata-spezifischem membran-antigen in serum
US20030224011A1 (en) * 2001-05-29 2003-12-04 Conley Anthony J Hepatitis c virus conjugates
JP2006514981A (ja) * 2002-12-03 2006-05-18 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｇｐ１２０特異抗原、その結合体；その調製と使用のための方法
WO2004073659A2 (en) * 2003-02-14 2004-09-02 Merck & Co., Inc. HIV gp120 MIMOTOPE ANTIGEN
KR20050114225A (ko) * 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
WO2005058968A1 (en) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa A method to make a peptide-carrier conjugate with a high immunogenicity
US20090047303A1 (en) * 2005-05-16 2009-02-19 Alan Shaw Method for improving the immunogenicity of plasmodium antigens
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
KR102289985B1 (ko) 2014-12-08 2021-08-17 삼성디스플레이 주식회사 표시 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762913A (en) * 1973-05-07 1988-08-09 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
JPH01500432A (ja) * 1986-07-21 1989-02-16 サウスウェスト・ファウンデーション・フォー・バイオメディカル・リサーチ Ａｉｄｓおよびａｒｃのウィルス原因物質に対して免疫化するための組成物および方法
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
EP0289110A3 (en) * 1987-02-02 1990-01-24 Swiss Serum and Vaccine Institute Berne Conjugate malaria vaccine
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
AU1711888A (en) * 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
IL87391A0 (en) * 1987-08-27 1989-01-31 Repligen Corp Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
NL8702403A (nl) * 1987-10-09 1989-05-01 Stichting Centr Diergeneeskund Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc.
JPH01190636A (ja) * 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
DE3802060A1 (de) * 1988-01-25 1989-07-27 Boehringer Mannheim Gmbh Hapten-protein-konjugate und ihre verwendung
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
WO1990003984A1 (en) * 1988-10-03 1990-04-19 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
CA2047078A1 (en) * 1990-07-19 1992-01-20 Steven S. Bondy Cyclic hiv principal neutralizing determinant peptides
DE4033714C3 (de) * 1990-10-24 1995-09-07 Brahms Diagnostica Gmbh Neues Hapten-Analytikum basierend auf dem Prinzip einer Antigen-Antikörper-Reaktion

Also Published As

Publication number Publication date
CA2047073A1 (en) 1992-01-20
PT98380A (pt) 1992-05-29
EP0467700A2 (en) 1992-01-22
KR920002633A (ko) 1992-02-28
NO912825L (no) 1992-01-20
FI913476A0 (fi) 1991-07-18
EP0467700A3 (en) 1993-03-10
US5606030A (en) 1997-02-25
AU8113591A (en) 1992-01-23
JPH0625300A (ja) 1994-02-01
IL98845A0 (en) 1992-07-15
JPH07113038B2 (ja) 1995-12-06
IE912558A1 (en) 1992-01-29
FI913476A (fi) 1992-01-20

Similar Documents

Publication Publication Date Title
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
ZA837603B (en) Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
GEP20032902B (en) Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV
DK93388A (da) Lav-virusvarianter, dna- og proteinbestanddele deraf og anvendelse deraf, saerlig til diagnostiske formaal og til fremstilling af immunogene praeparater
NO884795D0 (no) Rekombinant, humant immunoglobulin og fremgangsmaate for fremstilling av dette.
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
NO892251L (no) Fremgangsmaate ved fremstilling av kokkoidosevaksine ved rekombinante teknikker.
NO900577D0 (no) Cyklosporinholdige preparater og fremgangsmaate for deres fremstilling.
NO871025L (no) Polypeptid, dna og fremgangsmaate for fremstilling derav.
DE69531793D1 (de) Immunogene zubereitungen
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
WO1991015512A3 (en) Hiv envelope polypeptides
NZ239281A (en) Antigenic hiv conjugate, vaccine and pharmaceutical composition
DK196687D0 (da) Kombineret vaccine, samt fremgangsmaade til fremstilling deraf
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
EP0311228A3 (en) Recombinant polypeptides and their uses, including assay for aids virus
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
ZA915626B (en) Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties
AU2715288A (en) Human respiratory syncytialvirus vaccine derived from the 1a (9.5 kd) protein
AU1814792A (en) Immunogenic peptides or polypeptides of the bvd virus and related viruses, vaccines incorporating them or expressing them, methods and means of production thereof
NO924563D0 (no) Benzokinoksaliner, fremgangsmaate for deres fremstilling og farmasoeytiske preparater inneholdende de nevnte forbindelser
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.